Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Pamela A. Trail
A Phase I First-In-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Related publications
First-In-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-Her3 Monoclonal Antibody, in Patients With Metastatic or Advanced HER3-Positive Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
A Phase I First-In-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients With Advanced Cancer
Clinical Cancer Research
Cancer Research
Oncology
Anti-Pd-1 Monoclonal Antibody MEDI0680 in a Phase I Study of Patients With Advanced Solid Malignancies
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
A Phase I Study of Farletuzumab, a Humanized Anti-Folate Receptor Α Monoclonal Antibody, in Patients With Solid Tumors
Investigational New Drugs
Oncology
Pharmacology
A Phase 1 Study of Anti-TGFβ Receptor Type-Ii Monoclonal Antibody LY3022859 in Patients With Advanced Solid Tumors
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
First‐in‐human Phase I Study of E7090, a Novel Selective FGFR Inhibitor, in Patients With Advanced Solid Tumors
Cancer Science
Cancer Research
Medicine
Oncology
Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
First-In-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
